4 active not recruiting, 3 completed, 3 recruiting, 2 terminated. 8 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Active not recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
Follow ATM Gene Mutation: new trials by email Literature Review of ATM Gene Mutation trials Research Report on ATM Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device - BRCA Mutation, PALB2 Gene Mutation | Phase 2 | Completed | European Institute of Oncology | 110 | 2024-06-21 | 2026-09-11 |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors Olaparib, ASTX727 - BRCA1 Mutation, BRCA2 Mutation | Phase 1 | Active not recruiting | Varun Monga, MBBS | 13 | 2024-02-07 | 2026-10-20 |
| Combination Therapy in Cancers With Mutations in DNA Repair Genes Niraparib, Irinotecan - Metastatic Solid Tumor, BRCA1 Mutation | Phase 1 | Active not recruiting | University of California, San Francisco | 24 | 2023-05-23 | 2026-11-12 |
| An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care - BRCA1 Mutation, POLD1 Gene Mutation | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2022-12-01 | 2026-08-27 |
| Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of California, Davis | 11 | 2020-02-25 | 2026-05-14 |
| Prostate Cancer Genetic Risk Evaluation and Screening Study Prostate cancer screening - Prostatic Neoplasm, Prostate Cancer | Recruiting | Massachusetts General Hospital | 400 | 2020-02-12 | 2026-11-10 | |
| Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer Epacadostat, Pembrolizumab - ATM Gene Mutation, Deleterious BRCA1 Gene Mutation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-07-31 | 2019-05-30 | |
| Effects of Vitamin B3 in Patients With Ataxia Telangiectasia Vitamin B3 - Ataxia Telangiectasia, ATM Gene Mutation | Phase 2 | Completed | Radboud University Medical Center | 24 | 2019-03-18 | 2022-07-25 |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Carboplatin, Docetaxel, Laboratory Biomarker Analysis - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of Washington | 18 | 2018-08-24 | 2026-08-26 |
| Olaparib In Metastatic Breast Cancer Olaparib - Metastatic Breast Cancer, Invasive Breast Cancer | Phase 2 | Active not recruiting | Beth Israel Deaconess Medical Center | 114 | 2018-04-01 | 2026-01-05 |
| Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - ATM Gene Mutation, ATR Gene Mutation | Phase 2 | Completed | SWOG Cancer Research Network | 51 | 2017-03-03 | 2021-06-23 |
| The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. MRI pelvis or CT imaging under clinical management for Pr Ca, Whole body bone scan imaging, PET-CT imaging - Prostate Cancer, BRCA Mutation | Recruiting | Institute of Cancer Research, United Kingdom | 50 | 2015-10-15 | 2025-12-16 | |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Advanced Malignant Neoplasm, ATM Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 150 | 2014-12-22 | 2026-06-12 |
Prostatic Neoplasms (3) · Neoplasm Metastasis (2) · Ataxia Telangiectasia (1) · Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Fanconi Anemia, Complementation Group D1 (1) · Genetic Predisposition to Disease (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Turcot syndrome (1)
Neoplasms (7) · Neoplasms by Site (6) · Genital Diseases (3) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Male Urogenital Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Prostatic Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Breast Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · DNA Repair-Deficiency Disorders (2) · Digestive System Diseases (2)
niraparib (2) · olaparib (2) · talazoparib (2) · Carboplatin (1) · Docetaxel (1) · Irinotecan (1) · Magnetic Resonance Spectroscopy (1) · Niacinamide (1) · Standard of Care (1) · Tablets (1) · Tamoxifen (1) · decitabine and cedazuridine drug combination (1) · epacadostat (1) · nicotinamide-beta-riboside (1) · pembrolizumab (1)
M.D. Anderson Cancer Center (2) · Beth Israel Deaconess Medical Center (1) · European Institute of Oncology (1) · Institute of Cancer Research, United Kingdom (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Radboud University Medical Center (1) · SWOG Cancer Research Network (1) · University of California, Davis (1) · University of California, San Francisco (1) · University of Washington (1) · Varun Monga, MBBS (1)
United States (9) · Canada (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Varun Monga, MBBS (2) · Bernardo Bonanni, MD (1) · Heather H. Cheng (1) · Kenneth Offit, MD, MPH (1) · Keyan Salari, MD, PhD (1) · Marc Dall'Era (1) · Michel Willemsen, Prof. (1) · Milind Javle (1) · Nadine Tung, MD (1) · Rosalind A Eeles, FRCP FRCR (1) · Sarina A Piha-Paul (1) · Vassiliki Papadimitrakopoulou (1)
PMID 33119476, PMID 36710203, PMID 38453598, PMID 39226292, PMID 41604601
2023 (1), P30CA016672 (1), P30CA093373 (1), R01CA255613 (1), U10CA180888 (1)